Please login to the form below

Not currently logged in
Email:
Password:

Castleman's disease

This page shows the latest Castleman's disease news and features for those working in and with pharma, biotech and healthcare.

Roche snags pair of FDA breakthrough designations

Roche snags pair of FDA breakthrough designations

drug. In J-ALEX - conducted by Roche's Japanese subsidiary Chugai - Alecensa reduced the risk of disease-worsening or death by 66% compared to Xalkori. ... First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green

Latest news

  • Roche wins early use RA approval for RoActemra in Europe Roche wins early use RA approval for RoActemra in Europe

    Adds to existing indications in arthritis and Castleman’s disease. Roche's arthritis brand RoActemra (tocilizumab) has widened its European licence, winning a new EU indication to treat early rheumatoid arthritis. ... The study showed patients on the

  • EC approves Janssen rare blood disorder drug EC approves Janssen rare blood disorder drug

    Sylvant available to treat multicentric Castleman's disease. Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD). ... rare and challenging disease and further

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castlemans disease

    Sylvant approved to treat lymphoma-like condition. The US FDA has approved a new drug to treat a rare cancer-like condition known as multicentric Castleman's disease. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe. ... Castleman's disease is a rare disorder characterised by

  • J&J positive about pipeline

    The stable of products that are nearing readiness to be filed with regulators in the US and EU includes bapineuzumab IV for Alzheimer's disease, which the company acquired from Elan ... Also on the list are fulranumab for osteoarthritis pain; siltuximab

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics